Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

Finasteride is the most effective treatment for reducing DHT and addressing hair loss compared to fish oil and saw palmetto. Topical treatments like RU58841 and minoxidil are also discussed, but finasteride remains the most effective option.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Significant hair regrowth was achieved using oral finasteride and topical minoxidil over five months, with noticeable improvements in hairline and temple areas. The user experienced minimal side effects, mainly increased eyebrow and eyelash growth, and attributes additional physical improvements to weight loss and exercise.

A user discussed their hair transplant journey, using finasteride for five years, then switching to dutasteride and adding oral minoxidil. Another user congratulated them on their progress.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

The user experienced significant hair regrowth after 5 months using Minoxidil and Finasteride, specifically Hims chewables. They noted an increase in depression as a side effect.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

User shared a 5-month progress update on using topical minoxidil 6% and finasteride 0.05% once daily, with microneedling and vitamins. They experienced initial shedding but no side effects, and increased the treatment to twice daily after month 4.

A 22-year-old has been using finasteride and minoxidil for 5 years to combat aggressive male pattern baldness, but is considering switching to dutasteride due to worsening hair loss. Dutasteride is suggested as it may be more effective in reducing DHT levels for aggressive cases.

The user experienced significant hair regrowth and darkening after 4.5 months using 1 mg Finasteride and 5% Minoxidil. Despite improvements, they are still considering a hair transplant for a better hairline.

The conversation discusses a user's 1.5-year experience with oral minoxidil and dutasteride for hair loss, mentioning side effects like itchy nipples and ball ache. Specific treatments used are 5mg of minoxidil and 0.5mg of dutasteride daily.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

Dutasteride at 0.5 mg and 2.5 mg doses may eventually yield similar hair growth results over time, with 0.5 mg being sufficient for many users. Higher doses may not significantly increase benefits and could lead to diminished returns.

Some individuals experience hair loss despite using treatments like 2.5 mg dutasteride, finasteride, and minoxidil, suggesting sensitivity to DHT or other factors. Various treatments and lifestyle changes are discussed, but results vary, and some consider hair transplants or other solutions.

The user reported positive progress in hair growth after taking 5 mg of oral minoxidil daily and 2.5 mg of dutasteride three times a week, with noticeable changes in hair fullness and body hair growth. They experienced initial side effects at a higher dosage but reported no side effects at the current dosage and plan to continue updating their progress.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

A user is experiencing hair thinning and is using a peptide with oleanic acid as a DHT blocker, along with minoxidil, while waiting for topical finasteride. They plan to use a combination of minoxidil, finasteride, dermastamp, ketoconazole, and scalp massages, but are advised to stick to proven treatments like finasteride and minoxidil.

The user shared their five-month progress using topical minoxidil, oral finasteride, and dermarolling for hair regrowth, noting improvements despite some areas remaining thin. Other users suggested switching from dermarolling to dermastamping for safety and effectiveness.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

The user experienced hair loss and used a topical minoxidil and finasteride solution, which initially halted hair fall and increased thickness. After switching to oral finasteride, they experienced significant shedding without regrowth, leaving them worse off than before.

The user has been using a combination of oral and topical minoxidil, topical finasteride, RU58841, Nizoral, and microneedling for hair loss treatment. They report improvement in hair thickness except for the crown area, which has not changed.

A 33-year-old male shared his hair regrowth journey, using minoxidil, dermarolling, hair brushing, scalp oils, dietary changes, and supplements. After five months, he started finasteride to improve hair thickness.

A user discussed their hair transplant progress and mentioned using 1mg Finasteride, 5% Topical Minoxidil, and recently starting 5% RU58841. They are seeking advice on whether to use RU58841 at month 4 post-transplant.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.